In parallel, another approach distinguished five subsets of DLBCL, including two ABC-DLBCL groups, one with low risk and a possible marginal zone origin (C1), and the other a high-risk group (C5) enriched in cases with mutations in MYD88, CD79B, and PIM1; two subsets of GC-DLBCLs with favorable (C4) and poor (C3) outcomes, and an ABC/GC-independent group (C2) with biallelic inactivation of TP53, CDKN2A loss, and associated genomic instability [75]. This evidence concerns the gene MYD88 and diffuse large B-cell lymphoma.